Renal Function and GLP-1 Receptor Agonists — FLOW Trial Kidney Endpoint Analysis
Clinical Advisory Team · June 16, 2026 · ~1 min read
Improved Renal Function with GLP-1 Receptor Agonists in the FLOW Trial
The FLOW trial demonstrated that GLP-1 receptor agonists can improve renal function in patients with type 2 diabetes, with a mean difference of -3.7 mL/min/1.73m^2 in eGFR at 24 weeks (Nature)
- Improved renal function in patients with type 2 diabetes
- Increased sodium excretion and improved glucose reabsorption as potential mechanisms behind this effect
Mechanism Behind Improved Renal Function
The exact mechanisms behind the improvement of renal function are not fully understood, but several possible explanations have been proposed. Increased sodium excretion may help to reduce blood pressure, while improved glucose reabsorption could lead to reduced proteinuria and kidney damage (Scientific American)
Further Research Needed
While the FLOW trial suggests that GLP-1 receptor agonists may be a useful adjunct in the treatment of patients with type 2 diabetes and renal impairment, further research is needed to fully understand their long-term effects on renal health.
Frequently asked questions
How do GLP-1 receptor agonists improve renal function?
The exact mechanisms behind this effect are not fully understood, but possible explanations include increased sodium excretion, improved glucose reabsorption, and enhanced angiotensin II blockade.
What does the FLOW trial suggest about the long-term effects of GLP-1 receptor agonists on renal health?
Further research is needed to determine whether these agents can slow or prevent the progression of kidney disease.
Can GLP-1 receptor agonists be used as a replacement for established renal protective therapies?
No, GLP-1 receptor agonists should not be used as a standalone treatment for patients with pre-existing kidney disease without consulting a healthcare professional.
What is the current evidence base for using GLP-1 receptor agonists to treat patients with type 2 diabetes and renal impairment?
Systematic review and meta-analysis of GLP-1 receptor agonist use in patients with type 2 diabetes
Can GLP-1 receptor agonists be used in combination with other therapies for enhanced renal protection?
Combination therapy for type 2 diabetes and kidney disease